scispace - formally typeset
K

Katsutoshi Furukawa

Researcher at Tohoku Pharmaceutical University

Publications -  158
Citations -  8457

Katsutoshi Furukawa is an academic researcher from Tohoku Pharmaceutical University. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 46, co-authored 152 publications receiving 7593 citations. Previous affiliations of Katsutoshi Furukawa include National Institutes of Health & Tohoku University.

Papers
More filters
Journal ArticleDOI

Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation

TL;DR: Data suggest that TNFs protect hippocampal neurons against A beta toxicity by suppressing accumulation of ROS and Ca2+ and that kappa B-dependent transcription is sufficient to mediate these effects.
Journal ArticleDOI

Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons.

TL;DR: The data suggest that glutamate toxicity involves peroxide production, which contributes to loss of Ca2+ homeostasis, and that induction of antioxidant defense systems is a mechanism underlying the [Ca2+]i‐stabilizing and excitoprotective actions of neurotrophic factors.
Journal ArticleDOI

Alzheimer's Ps-1 mutation perturbs calcium homeostasis and sensitizes Pc12 cells to death induced by amyloid β-peptide

TL;DR: It is reported that expression of PS-1 mutation L286V in cultured PC12 cells exaggerates Ca2+ responses to agonists (carbachol and bradykinin), and an antagonist of voltage-dependent calcium channels (nifedipine), and a blocker of Ca2- release from ER (dantrolene), counteract the adverse consequences of the PS- 1 mutation.
Journal ArticleDOI

18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

TL;DR: A novel tau PET tracer is developed through compound optimization of arylquinoline derivatives that bound to neurofibrillary tangles selectively and with a higher signal-to-background ratio than did THK5117 in Alzheimer disease patients.